Should you buy Teva Pharma Industries Ltd stock now?
Yes, the technical signal for Teva Pharma Industries Ltd is currently BUY. Teva Pharma Industries Ltd trades at $34.53 as of 8/6/2026. The overall technical signal is: Strong Buy. The technical analysis shows the following: MACD is positive (bullish trend) at 0.392 with rising momentum (signal: -0.021); RSI is at 58.9 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $41.20 points to 19.3% upside. The stock is in a broader uptrend (above SMA50/SMA200). This is a technical observation based on current data, not investment advice.
What is the price target for Teva Pharma Industries Ltd stock?
The average analyst price target for Teva Pharma Industries Ltd is $41.20. The current price is $34.53, which gives an upside of 19.3%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $37.08 and $45.32.
Is Teva Pharma Industries Ltd a dividend stock?
No, Teva Pharma Industries Ltd does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Teva Pharma Industries Ltd stock?
Teva Pharma Industries Ltd is rated as a stock with moderate risk. the annual standard deviation is 40.2%, which classifies the stock as moderate risk.
Is Teva Pharma Industries Ltd overvalued?
No, Teva Pharma Industries Ltd is considered undervalued based on the analyst price target (19.3% upside). Teva Pharma Industries Ltd has the following valuation ratios: a P/E ratio of 57.4 (highly valued), a P/S ratio of 2.3, a P/B ratio of 5.3. The analyst price target suggests that the stock is undervalued by 19.3%.
Is Teva Pharma Industries Ltd overbought?
No, Teva Pharma Industries Ltd is not overbought. RSI is at 58.9 (neutral zone). The technical indicators show: RSI is at 58.9 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 5.9% above the 20-day average (short-term uptrend). In addition, MACD is positive with rising momentum (bullish).
When is the next Teva Pharma Industries Ltd earnings report?
The date of the next earnings report for Teva Pharma Industries Ltd has not been published yet. Check the company's investor calendar for updates.
Is Teva Pharma Industries Ltd shorted?
Yes, Teva Pharma Industries Ltd is shorted with 2.8% of the free float sold short. This is a moderate level of short selling, within the normal range for most stocks. Data is updated daily based on official filings with the SEC.
Are insiders buying Teva Pharma Industries Ltd stock?
No, insiders are not buying Teva Pharma Industries Ltd shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 8 sales. On a net basis, 13,101,388 $ worth of shares were sold. Across the last 20 reported transactions, the split is 0 purchases and 20 sales, with a net 26,826,116 $ sold. Active sellers include Jover Placid, Hughes Eric A, Shields Matthew and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Teva Pharma Industries Ltd a good stock?
Based on our total score, Teva Pharma Industries Ltd is rated as a mediocre stock with a total score of 49 out of 100. The stock scores around average on value, quality and momentum – it sits near the median in our database. The score is made up of Value: 33/100, Quality: 41/100, Momentum: 73/100. In addition: analysts see 19.3% upside to the price target; technical signal: Strong Buy. Whether Teva Pharma Industries Ltd is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Teva Pharma Industries Ltd stock?
The outlook for Teva Pharma Industries Ltd based on current data: the average analyst price target is $41.20 (+19.3%); the stock is in an uptrend (above SMA50 and SMA200); the P/E ratio is 57.4 (high – the market expects growth). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Teva Pharma Industries Ltd stock rising?
Teva Pharma Industries Ltd is rising right now. The technical indicators show: the price is 5.9% above the 20-day average; MACD is positive with rising momentum (bullish signal); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Teva Pharma Industries Ltd go?
The average analyst price target for Teva Pharma Industries Ltd is $41.20, which corresponds to a potential gain of 19.3% from the current price of $34.53. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Teva Pharma Industries Ltd fall?
We lack enough history to give a specific floor for Teva Pharma Industries Ltd. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Teva Pharma Industries Ltd do?
Teva Pharmaceutical Industries laver medicin og sælger det globalt. De tjener primært penge på at udvikle og producere kopimedicin, men de har også specialprodukter. Teva fremstiller alt fra tabletter og injektioner til plaster, og de driver forretning i Nordamerika, Europa og... The company belongs to the Sundhed sector, more specifically the Drug Manufacturers - Specialty & Generic industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Teva Pharma Industries Ltd as an investment.
Did Teva Pharma Industries Ltd raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Teva Pharma Industries Ltd. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Teva Pharma Industries Ltd making money or losing money?
Yes, Teva Pharma Industries Ltd is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 4.1% — which is modest. The operating margin (profit before interest and taxes) is 4.0%. At a P/E ratio of 57.4, you currently pay 57.4 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can Teva Pharma Industries Ltd go bankrupt?
The bankruptcy risk of Teva Pharma Industries Ltd is rated as elevated. Altman Z2 (a model for assessing financial distress) is -0.86 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 6 — which is average. Debt relative to equity is 625% (high). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Teva Pharma Industries Ltd have a lot of debt?
Yes, Teva Pharma Industries Ltd has elevated debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 625%. For the sundhed sector, anything above 150% counts as elevated — that raises the financial risk, especially if interest rates rise or earnings fall. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector. Can Teva Pharma Industries Ltd service its debt? Could struggle to service its debt — the interest coverage ratio (how many times earnings can cover interest payments) is 0.8x, and net debt equals 3.1 years of earnings (EBITDA).
